Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
bortezomib
i
Other names:
LDP 341, MG 341, MLN 341, NSC 681239, PS 341, JNJ-26866138, PS-341, PS 0341, PS0341, NSC681239, LDP-341, PS341, LDP341, MLN341, MLN-341, NSC-681239
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(90)
News
Trials
Company:
Generic mfg.
Drug class:
Proteasome inhibitor
Related drugs:
‹
ixazomib (31)
carfilzomib (18)
NPI-0052 (2)
MG132 (1)
AVA3996 (0)
CEP-18770 (0)
ONX 0912 (0)
ixazomib (31)
carfilzomib (18)
NPI-0052 (2)
MG132 (1)
AVA3996 (0)
CEP-18770 (0)
ONX 0912 (0)
›
Associations
(90)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
bortezomib + panobinostat
Sensitive: A1 - Approval
bortezomib + panobinostat
Sensitive
:
A1
bortezomib + panobinostat
Sensitive: A1 - Approval
bortezomib + panobinostat
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
bortezomib + pegylated liposomal doxorubicin
Sensitive: A1 - Approval
bortezomib + pegylated liposomal doxorubicin
Sensitive
:
A1
bortezomib + pegylated liposomal doxorubicin
Sensitive: A1 - Approval
bortezomib + pegylated liposomal doxorubicin
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
bortezomib
Sensitive: A1 - Approval
bortezomib
Sensitive
:
A1
bortezomib
Sensitive: A1 - Approval
bortezomib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
rituximab + bortezomib
Sensitive: A1 - Approval
rituximab + bortezomib
Sensitive
:
A1
rituximab + bortezomib
Sensitive: A1 - Approval
rituximab + bortezomib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
bortezomib
Sensitive: A1 - Approval
bortezomib
Sensitive
:
A1
bortezomib
Sensitive: A1 - Approval
bortezomib
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
lenalidomide + bortezomib
Sensitive: A2 - Guideline
lenalidomide + bortezomib
Sensitive
:
A2
lenalidomide + bortezomib
Sensitive: A2 - Guideline
lenalidomide + bortezomib
Sensitive
:
A2
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
bortezomib + elotuzumab
Sensitive: A2 - Guideline
bortezomib + elotuzumab
Sensitive
:
A2
bortezomib + elotuzumab
Sensitive: A2 - Guideline
bortezomib + elotuzumab
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
bortezomib
Sensitive: A2 - Guideline
bortezomib
Sensitive
:
A2
bortezomib
Sensitive: A2 - Guideline
bortezomib
Sensitive
:
A2
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
bortezomib
Sensitive: A2 - Guideline
bortezomib
Sensitive
:
A2
bortezomib
Sensitive: A2 - Guideline
bortezomib
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
rituximab + bortezomib
Sensitive: A2 - Guideline
rituximab + bortezomib
Sensitive
:
A2
rituximab + bortezomib
Sensitive: A2 - Guideline
rituximab + bortezomib
Sensitive
:
A2
No biomarker
Childhood B Acute Lymphoblastic Leukemia
No biomarker
Childhood B Acute Lymphoblastic Leukemia
bortezomib
Sensitive: A2 - Guideline
bortezomib
Sensitive
:
A2
bortezomib
Sensitive: A2 - Guideline
bortezomib
Sensitive
:
A2
No biomarker
Kaposi Sarcoma
No biomarker
Kaposi Sarcoma
bortezomib
Sensitive: A2 - Guideline
bortezomib
Sensitive
:
A2
bortezomib
Sensitive: A2 - Guideline
bortezomib
Sensitive
:
A2
Chr del(17)(p13)
Multiple Myeloma
Chr del(17)(p13)
Multiple Myeloma
bortezomib
Sensitive: A2 - Guideline
bortezomib
Sensitive
:
A2
bortezomib
Sensitive: A2 - Guideline
bortezomib
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
bortezomib
Sensitive: A2 - Guideline
bortezomib
Sensitive
:
A2
bortezomib
Sensitive: A2 - Guideline
bortezomib
Sensitive
:
A2
No biomarker
B Acute Lymphoblastic Leukemia
No biomarker
B Acute Lymphoblastic Leukemia
bortezomib
Sensitive: A2 - Guideline
bortezomib
Sensitive
:
A2
bortezomib
Sensitive: A2 - Guideline
bortezomib
Sensitive
:
A2
Chr t(11;14)
Multiple Myeloma
Chr t(11;14)
Multiple Myeloma
venetoclax + bortezomib
Sensitive: B - Late Trials
venetoclax + bortezomib
Sensitive
:
B
venetoclax + bortezomib
Sensitive: B - Late Trials
venetoclax + bortezomib
Sensitive
:
B
Chr del(17p)
Multiple Myeloma
Chr del(17p)
Multiple Myeloma
bortezomib + selinexor
Sensitive: B - Late Trials
bortezomib + selinexor
Sensitive
:
B
bortezomib + selinexor
Sensitive: B - Late Trials
bortezomib + selinexor
Sensitive
:
B
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
venetoclax + bortezomib + dexamethasone
Sensitive: B - Late Trials
venetoclax + bortezomib + dexamethasone
Sensitive
:
B
venetoclax + bortezomib + dexamethasone
Sensitive: B - Late Trials
venetoclax + bortezomib + dexamethasone
Sensitive
:
B
RPL5 expression
Multiple Myeloma
RPL5 expression
Multiple Myeloma
bortezomib
Sensitive: B - Late Trials
bortezomib
Sensitive
:
B
bortezomib
Sensitive: B - Late Trials
bortezomib
Sensitive
:
B
Chr del(17p)
Multiple Myeloma
Chr del(17p)
Multiple Myeloma
bortezomib
Sensitive: C2 – Inclusion Criteria
bortezomib
Sensitive
:
C2
bortezomib
Sensitive: C2 – Inclusion Criteria
bortezomib
Sensitive
:
C2
Chr t(11;14)
Multiple Myeloma
Chr t(11;14)
Multiple Myeloma
bortezomib
Sensitive: C3 – Early Trials
bortezomib
Sensitive
:
C3
bortezomib
Sensitive: C3 – Early Trials
bortezomib
Sensitive
:
C3
BRAF V600E
Multiple Myeloma
BRAF V600E
Multiple Myeloma
bortezomib
Sensitive: C3 – Early Trials
bortezomib
Sensitive
:
C3
bortezomib
Sensitive: C3 – Early Trials
bortezomib
Sensitive
:
C3
CD20 expression
Childhood B Acute Lymphoblastic Leukemia
CD20 expression
Childhood B Acute Lymphoblastic Leukemia
rituximab + bortezomib
Sensitive: C3 – Early Trials
rituximab + bortezomib
Sensitive
:
C3
rituximab + bortezomib
Sensitive: C3 – Early Trials
rituximab + bortezomib
Sensitive
:
C3
LDH elevation
Multiple Myeloma
LDH elevation
Multiple Myeloma
lenalidomide + bortezomib
Sensitive: C3 – Early Trials
lenalidomide + bortezomib
Sensitive
:
C3
lenalidomide + bortezomib
Sensitive: C3 – Early Trials
lenalidomide + bortezomib
Sensitive
:
C3
CD74 expression
Acute Myelogenous Leukemia
CD74 expression
Acute Myelogenous Leukemia
bortezomib
Sensitive: C3 – Early Trials
bortezomib
Sensitive
:
C3
bortezomib
Sensitive: C3 – Early Trials
bortezomib
Sensitive
:
C3
7-gene signature
Multiple Myeloma
7-gene signature
Multiple Myeloma
bortezomib
Sensitive: C3 – Early Trials
bortezomib
Sensitive
:
C3
bortezomib
Sensitive: C3 – Early Trials
bortezomib
Sensitive
:
C3
miR-33 underexpression
Multiple Myeloma
miR-33 underexpression
Multiple Myeloma
bortezomib
Resistant: C3 – Early Trials
bortezomib
Resistant
:
C3
bortezomib
Resistant: C3 – Early Trials
bortezomib
Resistant
:
C3
Chr t(4;14)
Multiple Myeloma
Chr t(4;14)
Multiple Myeloma
bortezomib
Resistant: C3 – Early Trials
bortezomib
Resistant
:
C3
bortezomib
Resistant: C3 – Early Trials
bortezomib
Resistant
:
C3
Chr del(13q)
Multiple Myeloma
Chr del(13q)
Multiple Myeloma
bortezomib
Resistant: C3 – Early Trials
bortezomib
Resistant
:
C3
bortezomib
Resistant: C3 – Early Trials
bortezomib
Resistant
:
C3
S100A9 expression
Multiple Myeloma
S100A9 expression
Multiple Myeloma
bortezomib + panobinostat
Resistant: C3 – Early Trials
bortezomib + panobinostat
Resistant
:
C3
bortezomib + panobinostat
Resistant: C3 – Early Trials
bortezomib + panobinostat
Resistant
:
C3
S100A8 expression
Multiple Myeloma
S100A8 expression
Multiple Myeloma
bortezomib + panobinostat
Resistant: C3 – Early Trials
bortezomib + panobinostat
Resistant
:
C3
bortezomib + panobinostat
Resistant: C3 – Early Trials
bortezomib + panobinostat
Resistant
:
C3
CCND1 overexpression
Multiple Myeloma
CCND1 overexpression
Multiple Myeloma
bortezomib
Sensitive: C3 – Early Trials
bortezomib
Sensitive
:
C3
bortezomib
Sensitive: C3 – Early Trials
bortezomib
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login